Louis Staudt says his goal is to “continue to define [molecular] cancer subtypes because they are not going away, they are a part of nature”

Cancers are inherently diverse, capable of arising from cells at various stages of development and driven by numerous molecular mechanisms. Louis M. Staudt, M.D., Ph.D., has pioneered molecular classification of cancers, specifically lymphomas. His discoveries in defining cancer subtypes have been instrumental in the progress of diagnostics and precision medicine, specifically his characterization of molecular subtypes within diffuse large B-cell lymphomas. For these pivotal discoveries, Dr. Staudt has been recognized by this year’s AACR Award for Outstanding Achievement in Blood Cancer Research. As the chief of the NCI Lymphoid Malignancies Branch, Dr. Staudt’s current work explores new ways to define and target lymphoid malignancies, including through epigenetic and immunologic mechanisms. Speaking with Blood Cancer Discovery’s Abigail Cleveland, Dr. Staudt shares his career experience on...

You do not currently have access to this content.